Published in Vaccine Weekly, March 8th, 2000
In his presentation on behalf of the Southwest Oncology Group, Dr. Vernon Sondak of the University of Michigan reported results indicating that Corixa's Melacine vaccine may benefit patients, in particular those with thinner tumors.
The Phase III clinical trial was designed by the Southwest Oncology Group with the primary study endpoint being the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.